Familial dilated cardiomyopathy with conduction defect due to LMNA mutation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:300751OMIM:115200I42.0
Who is this for?
Show terms as
1Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial dilated cardiomyopathy with conduction defect due to LMNA mutation is a genetic heart condition caused by changes (mutations) in the LMNA gene. This gene provides instructions for making proteins called lamin A and lamin C, which help maintain the structure of the cell's nucleus. When these proteins don't work properly, the heart muscle becomes weakened and stretched (dilated), making it harder for the heart to pump blood effectively. This condition is sometimes called LMNA-related dilated cardiomyopathy or laminopathy-associated cardiomyopathy. A hallmark feature of this disease is that it affects not only the heart muscle but also the heart's electrical system. Patients often develop problems with the heart's rhythm and conduction — the way electrical signals travel through the heart. This can lead to an abnormally slow heartbeat (bradycardia), irregular heartbeats (arrhythmias), or heart block, where signals between the upper and lower chambers of the heart are delayed or blocked. Atrial fibrillation and ventricular tachycardia are particularly common and dangerous complications. Symptoms typically begin in early to mid-adulthood and may include fatigue, shortness of breath, palpitations, dizziness, and fainting. The disease tends to progress over time, and there is a significant risk of sudden cardiac death due to dangerous heart rhythms. Treatment focuses on managing heart failure with medications, implanting pacemakers or defibrillators to address rhythm problems, and in severe cases, heart transplantation. Early diagnosis through genetic testing in affected families is important because preventive measures like defibrillator implantation can be life-saving.

Key symptoms:

Shortness of breath, especially during activity or when lying downUnusual tiredness and fatigueHeart palpitations or feeling like the heart is racing or skipping beatsDizziness or lightheadednessFainting or near-fainting episodesSwelling in the legs, ankles, or feetSlow heart rateIrregular heartbeatChest pain or discomfortDifficulty exercising or reduced ability to be physically activeSudden cardiac arrest in severe casesSwollen abdomen due to fluid buildupDifficulty breathing when lying flat

Clinical phenotype terms (17)— hover any for plain English
Cardiac conduction abnormalityHP:0031546Abnormal myocardium morphologyHP:0001637Atrial fibrillationHP:0005110Abnormal left ventricular functionHP:0005162LipodystrophyHP:0009125Ventricular arrhythmiaHP:0004308Atrial flutterHP:0004749Supraventricular tachycardiaHP:0004755Heart blockHP:0012722Sinoatrial blockHP:0012723Abnormal lymphocyte physiologyHP:0031409
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

1 event
Feb 2026A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Kardigan, Inc. — PHASE2, PHASE3

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →

No specialists are currently listed for Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial dilated cardiomyopathy with conduction defect due to LMNA mutationForum →

No community posts yet. Be the first to share your experience with Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

Start the conversation →

Latest news about Familial dilated cardiomyopathy with conduction defect due to LMNA mutation

No recent news articles for Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my heart condition right now, and how quickly might it progress?,Do I need an implantable defibrillator (ICD) now, or can we wait and monitor?,What specific LMNA mutation do I have, and does it tell us anything about my likely disease course?,Should my family members be tested for this mutation, and how should we arrange that?,Are there any physical activities I should avoid or limit?,What symptoms should prompt me to go to the emergency room immediately?,Are there any clinical trials or new treatments being studied for LMNA-related cardiomyopathy that I might be eligible for?

Common questions about Familial dilated cardiomyopathy with conduction defect due to LMNA mutation

What is Familial dilated cardiomyopathy with conduction defect due to LMNA mutation?

Familial dilated cardiomyopathy with conduction defect due to LMNA mutation is a genetic heart condition caused by changes (mutations) in the LMNA gene. This gene provides instructions for making proteins called lamin A and lamin C, which help maintain the structure of the cell's nucleus. When these proteins don't work properly, the heart muscle becomes weakened and stretched (dilated), making it harder for the heart to pump blood effectively. This condition is sometimes called LMNA-related dilated cardiomyopathy or laminopathy-associated cardiomyopathy. A hallmark feature of this disease is

How is Familial dilated cardiomyopathy with conduction defect due to LMNA mutation inherited?

Familial dilated cardiomyopathy with conduction defect due to LMNA mutation follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial dilated cardiomyopathy with conduction defect due to LMNA mutation typically begin?

Typical onset of Familial dilated cardiomyopathy with conduction defect due to LMNA mutation is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Familial dilated cardiomyopathy with conduction defect due to LMNA mutation?

Yes — 1 recruiting clinical trial is currently listed for Familial dilated cardiomyopathy with conduction defect due to LMNA mutation on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.